Opendata, web and dolomites


A 3D advanced test for prediction of drug response in secondary liver cancer

Total Cost €


EC-Contrib. €






 SpheroPredict project word cloud

Explore the words cloud of the SpheroPredict project. It provides you a very rough idea of what is the project "SpheroPredict" about.

liver    metastatic    risked    financial    toxicity    cancers    time    metastasizing    commercialisation    warrant    feasibility    created    healthcare    biologically    clear    spheropredict    heterogeneous    designed    personalised    patients    tumours    entail    primary    efficacy    efficient    21st    individualised    urgent    medicine    life    dealing    treatment    survival    quality    secondary    death    deaths    published    first    incurred    spheroid    international    de    migrating    alleviate    cancer    perspectives    treatments    innovative    platform    fail    therapy    era    treat    error    diseases    chemoresistance    inefficient    burden    drug    accurate    line    micro    cycle    cells    drugs    causes    3d    trial    tumour    therapies    worldwide    regarding    commercial    installing    chemotherapy    economic    predict    century    options    deathliest    productivity    lack    solution    locations    model    proven    types    spherotec    guidelines    patient    risk    guideline    body   

Project "SpheroPredict" data sheet

The following table provides information about the project.


Organization address
postcode: 82152
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website - -
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2017-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SPHEROTEC GMBH DE (MARTINSRIED) coordinator 50˙000.00


 Project objective

Cancer remains one of the deathliest diseases of the 21st century, with more than 1.9 M deaths per year in Europe. Some tumours entail a high risk of metastasizing, meaning that they are able to reach other locations in the body. Migrating cells from a primary tumour often cause secondary cancer in the liver, which is one of the leading causes of death worldwide.Regarding treatment options, international institutions have published clear guidelines about first line treatments to treat particular types of primary cancers. However, when dealing with secondary cancers (like metastatic liver cancer) there is a heterogeneous and very wide range of treatment options and no clear guidelines. The choice of treatment in secondary cancer is based in “trial and error”. This “trial and error” approach causes many patients fail to respond to therapy due to chemoresistance (lack of response to chemotherapy). In response, we at SpheroTec have created SpheroPredict, an individualised drug testing platform designed to predict the patient’s response to guideline therapies before installing the treatment cycle. Using cancer cells from the patient’s tumour, we build an accurate and biologically relevant 3D micro-tumour (spheroid) model to test the drugs and analyse the response in advance. In the end, only drugs with proven efficacy and low toxicity will be applied in the patient’s therapy cycle. In the era of personalised medicine and with the urgent need for de-risked and efficient drug treatments, we have developed an innovative solution that will greatly improve the patient’s survival time, quality of life and will help to alleviate the economic burden on the EU healthcare system incurred by inefficient therapies and productivity loss. Thus, in Phase 1, we aim to warrant the feasibility of the SpheroPredict project from the technical, commercial and financial perspectives, in order to ensure its success upon commercialisation.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SPHEROPREDICT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SPHEROPREDICT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More